FDA rejects Capricor Duchenne therapy over data violations
The FDA declined to approve Capricor Therapeutics’ deramiocel, an experimental cell therapy for Duchenne muscular dystrophy, citing serious problems with the Phase 3 trial, including unauthorized changes to its statistical plan and violations of blinding procedures. The agency said these issues made the results unreliable and could not be corrected after the fact; it also noted that the trial failed to meet its prespecified efficacy endpoints. Capricor maintains that its data support approval and can respond to the FDA’s inspection findings, but the rejection is a major setback for the company and patients with few treatment options.







